bioRxivBiophysicsPreprint
Discovery of non-nucleoside inhibitors of the enterovirus D68 3D polymerase through crystallographic fragment and high-throughput biochemical screening
Iman BiswasiD, Qinghui WangiD, Jack T. McCanniD, Egor P. TchesnokoviD, Linh NguyeniD, Manisha SainiiD, Jocelyn Cantero, Jezrael L. RevaldeiD, Matthias GötteiD, Adam R. RensloiD, R. Jeffrey NeitziD, Michelle R. ArkiniD, Eddy ArnoldiD, Francesc X. RuiziD
Abstract
Enterovirus D68 (EV-D68) is a non-polio picornavirus that has caused increasing rates of severe respiratory illness and acute flaccid myelitis in children worldwide this century. There are no approved vaccines or antivirals for EV-D68. Thus, we conducted a crystallographic fragment screening (CFS) and a high-throughput screening (HTS) biochemical assay against the EV-D68 RNA-dependent RNA polymerase 3D (3Dpol) to identify ligandable sites and non-nucleoside compounds that can spearhead anti-enteroviral drug discovery. The CFS, involving 650 fragments, identified 68 hit compounds (~10% hit rate) distributed across 3Dpol, including the functionally relevant sites RNA template channel, Active site, and RNA primer channel, and the previously unknown "Thumb site II" and "Index-middle finger pocket". Inhibition assays confirmed that compounds binding to each site can inhibit EV-D68 3Dpol activity. The HTS, a fluorescence-based PicoGreen biochemical assay, permitted screening 50,000 compounds of the ChemBridge Premium Library (0.77% hit rate). After a second-round dose-response screening, we identified 5-aminoindazole as a promising scaffold that inhibits EV-D68 3Dpol, including hit-to-lead compound 727590, which displayed an IC50 value of 25 M and preliminary structure-activity relationships. These hits offer amenable starting points for discovery and development of non-nucleoside inhibitors and provide opportunities for structure-based drug design against enteroviruses. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=107 SRC="FIGDIR/small/737532v1_ufig1.gif" ALT="Figure 1"> View larger version (35K): org.highwire.dtl.DTLVardef@1a7cb78org.highwire.dtl.DTLVardef@11f4bb9org.highwire.dtl.DTLVardef@1a477e0org.highwire.dtl.DTLVardef@ba5391_HPS_FORMAT_FIGEXP M_FIG Created with biorender.com and PyMOL Molecular Graphics System, version 2.5.0. Schrodinger, LLC. C_FIG
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Structure-Activity Relationship Studies Towards Analogues of Pleconaril as Novel Enterovirus-D68 Capsid-Targeting Antivirals
David L. Cousins, Ed Griffen, … Kris M. White·bioRxiv·Aug 8, 2025
- Crystallographic fragment screen of Enterovirus D68 3C protease and iterative design of lead-like compounds using structure-guided expansions
Ryan M. Lithgo, Charles W.E. Tomlinson, … F. von Delft·bioRxiv·Apr 29, 2024
- Crystallographic fragment screening of the dengue virus polymerase reveals multiple binding sites for the development of non-nucleoside antiflavivirals
Manisha Saini, Jasmin Cara Aschenbrenner, … Eddy Arnold·Journal of Medicinal ChemistryPeer-reviewed·Sep 2, 2025
- Strain dependent structural effects and in vivo efficacy of enterovirus-D68 inhibitors
T. R. Lane, J. Fu, … S. Ekins·bioRxiv·Dec 24, 2021
- Development of Enterovirus anti-viral agents that target the viral 2C protein
R. Kejriwal, T. Evans, … S. White·bioRxiv·Oct 6, 2022
- Crystallographic Fragment Screen of Coxsackievirus A16 2A Protease identifies new opportunities for the development of broad-spectrum anti-enterovirals
Ryan M. Lithgo, Charles W.E. Tomlinson, … F. von Delft·bioRxiv·Apr 29, 2024